BIOREVERT INC. TO PRESENT AT BIOTECH SHOWCASE™ 2024
Developing first-in-class anti-cancer drugs using MObyDiCK platform.
San Francisco / Jan. 9th, 2024 – Biorevert Inc. (“biorevert”), today announces that their Co-founder and Chief Global Strategist, Sea Choi, Ph.D., will present at the upcoming Biotech Showcase™ 2024.
Biorevert, which was found with proven records of scientific achievements to be translated into reversion therapies for patients, will be presenting their goals and purposes in treating cancer without any side effects. Conventional chemotherapy kills not only cancer cells but also fast-growing normal cells which cause serious side effects. Malignant tumors have a high recurrence rate after undergoing cytotoxic/targeted therapies since these cancer cells are managed to survive and fill the empty spaces of those already killed. Moreover, despite the recent development of immunotherapy, its efficacy is very limited to a certain group of patients, and it has side effects such as inducing autoimmune diseases with potential recurrence for long-term treatment. These critical limitations of conventional cancer therapies are due to their commonly shared goal for cancer treatment, which is only to target and kill cancer cells.
To overcome such limitations, biorevert introduces a different and innovative concept of anti-cancer therapy, ‘reversion therapy,’ to reprogram cancer cells into normal-like cells rather than destroying them. The development of therapeutic agents for such a purpose has a propounding meaning as a revolutionary anti-cancer treatment that can offer the possibility of managing cancer as a chronic disease without any side effects.
“A new era for cancer therapy has come; the era of cancer being managed and cared with our reversion therapy just as obesity medications that recently gained so much popularity,” said Choong-Hwan Lee, Co-founder and CEO of biorevert.
“To realize our dream to find cures for cancer, we will utilize our AI- and systems biology-based MObyDiCK platform to analyze a tremendous amount of data derived from patients and cell lines that are exponentially increasing to improve the quality of life for cancer patients,” said Kwang-Hyun Cho, Co-founder and CSO of biorevert.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that biorevert will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
The details of the biorevert presentation at Biotech Showcase are as follows:
Date: Tuesday, January 9th, 2024
Time: 9:30 AM
Track: Franciscan D (Ballroom Level)
ABOUT biorevert.
Biorevert is a faculty start-up biotech company with their novel first-in-class targets in colon, lung, and liver cancers identified by their AI- and systems biology-based platform called MObyDiCK platform.
MObyDiCK, Mechanistic target Optimization by Discovering and Controlling Network, is biorevert’s innovative proprietary platform for first-in-class target identification and its mechanism of actions (MOA). Once it’s optimized, biorevert plans to further validate their platform by enhancing its built-in drug discovery algorithms for a potential public release as a service in mid 2025.
Biorevert currently has seven pipelines under development both autonomously and collaboratively with leading biotech companies in south Korea. Four of their pipelines in the process of hit-finding, and other three pipelines are in the hit-to-lead process. They are also autonomously developing one of their pipelines as a small molecule and a gene therapy using adeno-associated virus, which is currently in in vivo Proof of Concept process.
For further information, please visit www.biorevert.com.
BIOREVERT INC. TO PRESENT AT BIOTECH SHOWCASE™ 2024
Developing first-in-class anti-cancer drugs using MObyDiCK platform.
San Francisco / Jan. 9th, 2024 – Biorevert Inc. (“biorevert”), today announces that their Co-founder and Chief Global Strategist, Sea Choi, Ph.D., will present at the upcoming Biotech Showcase™ 2024.
Biorevert, which was found with proven records of scientific achievements to be translated into reversion therapies for patients, will be presenting their goals and purposes in treating cancer without any side effects. Conventional chemotherapy kills not only cancer cells but also fast-growing normal cells which cause serious side effects. Malignant tumors have a high recurrence rate after undergoing cytotoxic/targeted therapies since these cancer cells are managed to survive and fill the empty spaces of those already killed. Moreover, despite the recent development of immunotherapy, its efficacy is very limited to a certain group of patients, and it has side effects such as inducing autoimmune diseases with potential recurrence for long-term treatment. These critical limitations of conventional cancer therapies are due to their commonly shared goal for cancer treatment, which is only to target and kill cancer cells.
To overcome such limitations, biorevert introduces a different and innovative concept of anti-cancer therapy, ‘reversion therapy,’ to reprogram cancer cells into normal-like cells rather than destroying them. The development of therapeutic agents for such a purpose has a propounding meaning as a revolutionary anti-cancer treatment that can offer the possibility of managing cancer as a chronic disease without any side effects.
“A new era for cancer therapy has come; the era of cancer being managed and cared with our reversion therapy just as obesity medications that recently gained so much popularity,” said Choong-Hwan Lee, Co-founder and CEO of biorevert.
“To realize our dream to find cures for cancer, we will utilize our AI- and systems biology-based MObyDiCK platform to analyze a tremendous amount of data derived from patients and cell lines that are exponentially increasing to improve the quality of life for cancer patients,” said Kwang-Hyun Cho, Co-founder and CSO of biorevert.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that biorevert will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
The details of the biorevert presentation at Biotech Showcase are as follows:
Date: Tuesday, January 9th, 2024
Time: 9:30 AM
Track: Franciscan D (Ballroom Level)
ABOUT biorevert.
Biorevert is a faculty start-up biotech company with their novel first-in-class targets in colon, lung, and liver cancers identified by their AI- and systems biology-based platform called MObyDiCK platform.
MObyDiCK, Mechanistic target Optimization by Discovering and Controlling Network, is biorevert’s innovative proprietary platform for first-in-class target identification and its mechanism of actions (MOA). Once it’s optimized, biorevert plans to further validate their platform by enhancing its built-in drug discovery algorithms for a potential public release as a service in mid 2025.
Biorevert currently has seven pipelines under development both autonomously and collaboratively with leading biotech companies in south Korea. Four of their pipelines in the process of hit-finding, and other three pipelines are in the hit-to-lead process. They are also autonomously developing one of their pipelines as a small molecule and a gene therapy using adeno-associated virus, which is currently in in vivo Proof of Concept process.
For further information, please visit www.biorevert.com.